Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

Antonio Anzueto, Gary T. Ferguson, Greg Feldman, Kenneth Chinsky, Allan Seibert, Amanda Emmett, Katharine Knobil, Dianne O'Dell, Christopher Kalberg, Glenn Crater

Research output: Contribution to journalArticlepeer-review

128 Scopus citations


Prevention and treatment of COPD exacerbations are recognized as key goals in disease management. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250 mcg/50 mcg (FSC 250/50) and salmeterol 50 mcg (SAL) twice-daily on moderate/severe exacerbations. Subjects received treatment with FSC 250/50 during a one month run-in, followed by randomization to FSC 250/50 or SAL for 52 weeks. Moderate/severe exacerbations were defined as worsening symptoms of COPD requiring antibiotics, oral corticosteroids and/or hospitalization. In 797 subjects with COPD (mean FEV1 0.98L, 34 predicted normal), treatment with FSC 250/50 significantly reduced the annual rate of moderate/severe exacerbations by 30.4 compared with SAL (1.10 and 1.59 per subject per year, respectively, p < 0.001), the annual rate of exacerbations requiring oral corticosteroids by 34 (p < 0.001) and the annual rate of moderate/severe exacerbations requiring hospitalization by 36 (p 0.043). Clinical improvements observed during run-in treatment with FSC 250/50 were better maintained over 52 weeks with FSC 250/50 compared to SAL. Statistically significant reductions in albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life were seen with FSC 250/50 compared with SAL. The incidence of adverse events was similar across groups. Pneumonia was reported more frequently with FSC 250/50 compared with SAL (7 vs. 2). FSC 250/50 is more effective than SAL at reducing the rate of moderate/severe exacerbations. These data confirm the beneficial effect of FSC on the management of COPD exacerbations and support the use of FSC in patients with COPD.

Original languageEnglish (US)
Pages (from-to)320-329
Number of pages10
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Issue number5
StatePublished - 2009


  • Chronic obstructive pulmonary disease (COPD)
  • Exacerbations
  • Fluticasone propionate
  • Inhaled corticosteroid
  • Long-acting beta2-agonist
  • Salmeterol

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes'. Together they form a unique fingerprint.

Cite this